Decreased release of the angiogenic peptide vascular endothelial growth factor in alzheimer's disease: Recovering effect with insulin and DHEA sulfate

Dementia and Geriatric Cognitive Disorders

Volumn 19, Issue 1, 2005, Pages 1-10

  Solerte, Sebastiano Bruno ^a   Ferrari, Ettore ^a   Cuzzoni, Gianni ^d   Locatelli, Eleonora ^a   Giustina, Andrea ^b   Zamboni, Mauro ^c   Schifino, Nicola ^d   Rondanelli, Mariangela ^d   Gazzaruso, Carmine ^e   Fioravanti, Marisa ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d ASP S Margherita Geriatric Dept   (Italy)

^e IRCCS   (Italy)

Author keywords

Aging; Alzheimer's disease; Amyloid peptides; Dehydroepiandrosterone sulfate; Immunity; Insulin; Natural killer cells; Neurodegeneration; Vascular dementia; Vascular endothelial growth factor

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CD16 ANTIGEN; CD56 ANTIGEN; INSULIN; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; PEPTIDE; PRASTERONE SULFATE; VASCULOTROPIN;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ANGIOGENESIS; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOMAGNETIC SEPARATION; INCUBATION TIME; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN SECRETION; RELAPSE; STATISTICAL SIGNIFICANCE;

ADULT; AGE FACTORS; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANGIOGENIC PROTEINS; BRAIN; CELLS, CULTURED; DEHYDROEPIANDROSTERONE; DEMENTIA, VASCULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INSULIN; KILLER CELLS, NATURAL; MALE; MICROCIRCULATION; MIDDLE AGED; PEPTIDE FRAGMENTS; REFERENCE VALUES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 20844441406     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080963     Document Type: Article

References (52)

1. Perlmutter LS, Chui HC, Saperia D, Athanikar J: Microangiopathy and the colocalization of heparan sulfate proteoglycan with amyloid in senile plaques of Alzheimer's disease. Brain Res 1990;508:13-19.
2. De la Torre JC, Mussivand T: Can a disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 1993;15:146-153.
3. De la Torre JC: Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology 1997;43:26-43.
4. Snowdown DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer's disease. The nun study. JAMA 1997;277:813-817.
5. Kalaria RN: Cerebral vessels in aging and Alzheimer's disease. Pharmacol Ther 1996;72:193-214.
6. McCourt M, Wang JH, Sookhai S, Redmond HP: Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999;134:1325-1331.
7. Frohman EM, Frohman TC, Gupta S, de Fourgerolles A, van der Noort S: Expression of intracellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. J Neurol Sci 1991;106:105-111.
8. Grammas P: A damaged microcirculation contributes to neuronal cell death in Alzheimer's disease. Neurobiol Aging 2000;21:199-205.
9. Plate KH: Mechanism of angiogenesis in the brain. J Neuropathol Exp Neurol 1999;58:313-320.
10. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;59:843-846.
11. Krupinski J, Kumar P, Kumar S, Kaluza J: Increased expression of TGF-β1 in brain tissue after ischemic stroke in humans. Stroke 1996;27:852-857.
12. Behzadian MA, Wang X-L, Shabrawey M, Caldwell RB: Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-β. Glia 1998;24:216-225.
13. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985.
14. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312.
15. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
16. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
17. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
18. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW: The vascular endothelial growth factor family of polypeptides. J Biol Chem 1991;47:211-218.
19. Werther K, Christensen IJ, Nielsen HJ: Determination of vascular endothelial growth factor (VEGF) in circulating blood: Significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002;62:343-350.
20. Solerte SB, Fioravanti M: Downregulation of vascular endothelial growth factor generation from immune cells in Alzheimer's disease. Neurobiol Aging 2002;23(suppl 1):S532.
21. Solerte SB, Fioravanti M: Human insulin upregulates the release of vascular endothelial growth factor (VEGF) from immune cells in hyperinsulinemic microalbuminuric Type 2 diabetic patients. Diabetologia 2002;45(suppl 2):A35.
22. Zhu Y, Jin K, Mao XO, Greenberg DA: Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression. FASEB J 2003;17:186-193.
23. Svensson B, Peters M, Konig HG, Poppe M, Levkau B, Rothermundt M, Arolt V, Kogel D, Prehn JH: Vascular endothelial growth factor protects cultured rat hippocampal neurons against hypoxic injury via an antiexcitotoxic, caspase-independent mechanism. J Cereb Blood Flow Metab 2002;22:1170-1175.
24. Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, Lust WD: Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 1998;12:101-105.
25. Jin KL, Mao XO, Greenberg DA: Vascular endothelial growth factor: Direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 2000;97:10242-10247.
26. Oosthuyse B, Moons L, Storkebaum E, Carmeliet P: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-137.
27. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski, Kumar P: Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002;23:237-243.
28. Solerte SB, Cerutti N, Mirani M, Ceresini G, Giustina A, Ferrari E, Fioravanti M: Impairment of secretory pattern of IGF-I from lymphomononuclear cells in aging and dementia of the Alzheimer's and vascular type. J Endocrinol Invest 2002;25:47-50.
29. Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hijmans W, Kennes B, Muller-Hermelink HF, Steinman GC: Admission criteria for immunogerontological studies in man: The SENIEUR protocol. Mech Ageing Dev 1984;28:47-55.
30. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3 revised. Washington, American Psychiatric Association, 1987.
31. McKhann G, Drachman D, Folstein M, Katzmann R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Workgroup under the auspices of Department of Healthy and Human services task force on Alzheimer's disease. Neurology 1984;34:939-944.
32. Roman GC, Tatemichi TK, Erkinjunnti T: Vascular dementia diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
33. Hachinski VC, Lassen NA, Marshall J: Multiinfarct dementia: A cause of mental deterioration in the elderly. Lancet 1974;ii:207-210.
34. Wehham PR, Price WH, Blundell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;ii:1158-1159.
35. Folstein M, Folstein S, McHugh PR: Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
36. Solerte SB, Fioravanti M, Schifino N, Cuzzoni G, Fontana I, Vignati G, Govoni S, Ferrari E: Dehydroepiandrosterone sulfate decreases the interleukin-2 mediated overactivity of the natural killer cell compartment in senile dementia of the Alzheimer's type. Dement Geriatr Cogn Disord 1999;10:21-27.
37. Solerte SB, Fioravanti M, Vignati G, Giustina A, Cravello L, Ferrari E: Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. J Clin Endocrinol Metab 1999;84:3260-3267.
38. Solerte SB, Ceresini G, Ferrari E, Fioravanti M: Hemorheologic changes and overproduction of cytokines from immune cells in mild to moderate dementia of the Alzheimer's type: Adverse effects on cerebromicrovascular system. Neurobiol Aging 2000;21:271-281.
39. Lackey BR, Gay SL, Henricks DM: Actions and interactions of the IGF system in Alzheimer's disease: Review and hypothesis. Growth Horm IGF Res 2000;10:1-13.
40. Jafferali S, Dumont Y, Sotty F, Robitaille Y, Quirion R, Kar S: Insulin-like growth factor-I and its receptor in the frontal cortex, hippocampus and cerebellum of normal human and Alzheimer disease brain. Synapse 2000;38:450-459.
41. Solerte SB, Gornati R, Cravello L, Albertelli N, Oberti S, Perotta D, Rossi G, Cuzzoni G, Ferrari E, Fioravanti M: Dehydroepiandrosterone-sulfate (DHEAS) restores the release of IGF-I from natural killer (NK) immune cells in old patients with dementia of Alzheimer's type (DAT). J Endocrinol Invest 1999;22:32-34.
42. Baxter JB, Blalock JE, Weigent DA: Characterization of immunoreactive insulin-like growth factor I from leukocytes and its regulation by growth hormone. Endocrinology 1991;129:1727-1734.
43. Gruden G, Araf S, Zonca S, Burt D, Thomas S, Gnudi L, Viberti GC: IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism. Kidney Int 2003:63:1249-1255.
44. Dik MG, Pluijm SMF, Jonker C, Deeg DJH, Lomecky MZ, Lips P: Insulin-like growth factor I (IGF-I) and cognitive decline in older persons. Neurobiol Aging 2003;24:573-581.
45. Martin D, Salinas M, Lopez-Valdaliso R, Serrano E, Recuero M, Cuadrado A: Effect of the Alzheimer amyloid fragment Abeta (25-35) on Akt/PKB kinase and survival of PC12 cells. J Neurochem 2001;78:1000-1008.
46. Wei W, Wand X, Kusiak JW: Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem 2002;277:17649-17656.
47. Suhara T, Magrané J, Rosen K, Christensen R, Kim H-S, Zheng B, McPhie DL, Walsh K, Querfurth H: Aβ42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3β signaling-dependent mechanism. Neurobiol Aging 2003;24:437-451.
48. Kureishi Y, Shiojima I, Bialik A, Fulton D, Lefer D, Sessa W: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010.
49. Jiang ZY, He Z, King BL, Kuroki T, Opland DM, Suzuma K, Suzuma I, Ueki K, Kulkarni RN, Kahn CR, King GL: Characterization of insulin's multiple signaling pathways in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem 2003;60:275-284.
50. Khorram O, Vu L, Yen SSC: Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol A Biol Sci Med Sci 1997;52:M1-M7.
51. Rubin J, Wandg H, Tashjian AH Jr, Patterson C: Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor 1. Endocrinology 1996;137:2262-2268.
52. 3H-1 myocytes. Biochem J 1989;261:927-934.